Separation and characterization of sialic acid-containing salivary-type amylase from patients' sera with immunoglobulin A-type myeloma

Moriyama, Takanori; Tozawa, Tatsuo; Yamashita, Hirohisa; Onodera, Sokichi; Nobuoka, Manabu; Makino, Mikio

doi:10.1016/0378-4347(91)80434-e

Cited by 12 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuraminidase treatment was performed at 37ºC for 1 h and the treated sample was analyzed by amylase isoenzyme electrophoresis. It was confirmed, using samples from previous reports that the results of both treatments did not differ between whole serum and a purified amylase fraction sample obtained by size-exclusion chromatography [25,26]. Whole sera were used for this treatment and the next reaction with monoclonal antibody, because the sample volumes were very low.…”

Section: Treatment With Neuraminidasesupporting

confidence: 62%

“…They reported that electrophoretic separation of the amylase revealed fast-migration forms in serum 10 of 47 (21.3%) patients with malignant ovarian neoplasms. Unfortunately, they did not characterize the fast-migrating amylase isoenzyme forms [45], however, it is considered in the perspective of today think and as "sialyl salivary-type amylase" similar to our reports [25,28,29]. In the following, describe the research results that led to the identification of the amylase found in the sera with ovarian cancer.…”

supporting

confidence: 50%

“…In contrast, Sudo and Kanno [24] reported so-called sialic-acid-containing amylase in the sera of patients with lung and pancreatic cancer. It was similarly detected in the sera of patients with IgA-type [25] and IgD-type multiple myeloma [26], and identified to be sialyl salivarytype amylase by electrophoretic study with neuraminidase treatment and immunological characterization [26]. In 2004, Shigemura et al [27] demonstrated, using cell culture and immunohistochemical techniques, that sialyl salivary-type amylase, together with normal salivary amylase (defined by electrophoretic characteristics), was produced by myeloma cells.…”

Section: Review Of Related Literaturementioning

confidence: 99%

See 2 more Smart Citations

Sialyl Salivary–Type Amylase Associated with Ovarian Cancer

Moriyama¹

2013

Cancer Treatment - Conventional and Innovative Approaches

Self Cite

View full text Add to dashboard Cite

The criteria were: a S3 to S2 ratio of over 1.0 and/or acidic fast-migrated sub-bands from S4 to S6. The sera were stored at-80ºC until required. A sample with a normal amylase isoenzyme electrophoretic pattern was used as control in the analyses of neuraminidase treatment, reaction with anti-salivary monoclonal antibody, and size-exclusion HPLC. 2.2. Measurement of total amylase activity Total serum amylase activity was measured on a Hitachi 7170 automated analyzer with G4-CNP as substrate (Toyobo, Osaka, Japan) at 37ºC. The reference interval of total serum amylase activity was from 40 to 160 U/L.

show abstract

Section: Treatment With Neuraminidasesupporting

confidence: 62%

supporting

confidence: 50%

Section: Review Of Related Literaturementioning

confidence: 99%

See 1 more Smart Citation

Sialyl Salivary–Type Amylase Associated with Ovarian Cancer

Moriyama¹

2013

Cancer Treatment - Conventional and Innovative Approaches

Self Cite

View full text Add to dashboard Cite

show abstract

“…30 th annual meeting Japanese Clinical Hematological SocietyB Wada et al 9 Tagawa et a/. lO Natazuka et al 11 Fujii et al 12 Moriyama et al 13 Moriyama at al. 13 Delannoy et al 14 Lopez et al 15 Hirota et al 16 Yamakawa et alY Nakajima et al 18 Bloemendal and Lobatto19 Nair et al 2O creatinine clearance ratio and the polyethylene glycol precipitation of <13%.…”

Section: Discussionmentioning

confidence: 99%

Hyperamylasaemia and multiple myeloma

Ross¹,

Devgun²,

Gunn³

2002

Annals of Clinical Biochemistry

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6] Recently, a few new clinical features associated with myeloma, such as salivary type hyperamylasemia [7][8][9][10][11][12][13] and elevation of the serum Creactive protein (CRP) concentration [14][15][16] and oncostatin M, 17 have been reported. Elevation of CRP is thought to be related to interleukin-6 (IL-6) production by myeloma cells, because of the identification of IL-6 as an autocrine and/or paracrine growth factor for myeloma cells.…”

Section: Introductionmentioning

confidence: 99%

In vitro excess ammonia production in human myeloma cell lines

et al. 1998

View full text Add to dashboard Cite

It is well known that cases with multiple myeloma reveal various clinical manifestations such as pancytopenia, hyperproteinemia, renal dysfunction, bone lesions, hypercalcemia and immunodeficiency. Recently, a few more clinical features associated with myeloma, such as salivary type hyperamylasemia and elevated serum C-reactive protein (CRP) concentration, have been reported. The elevation of CRP is thought to be related to interleukin-6 (IL-6) production by myeloma cells, because of identification of IL-6 as an autocrine and/or paracrine growth factor for myeloma cells. More recently, there have been several reports of cases with myeloma associated with hyperammonemia. This hyperammonemia is not considered to be due to liver dysfunction, because in most of these cases tests revealed normal hepatic function, and some cases showed different patterns of serum amino acid distribution than that associated with hepatic failure. However, there have been no apparent observations of ammonia production by myeloma cells. In this study, we used six human myeloma cell lines including KMS-18, which was recently established from a myeloma case associated with hyperammonemia. These lines were treated with MRA (mycoplasma removal agent) to observe ammonia production in vitro. They produced and released significantly higher levels of ammonia into culture medium than non-myeloma hematological cell lines or the HepG2 human hepatic carcinoma cell line. Although attempts to analyze the relative expression levels of the enzymes related to ammonia biosynthesis using the reverse transcriptase-polymerase chain reaction assay failed to detect any differences between these myeloma lines and other cell lines, in vitro excess ammonia production by the myeloma cells was confirmed and the relevance to clinical manifestations is discussed.

show abstract

Separation and characterization of sialic acid-containing salivary-type amylase from patients' sera with immunoglobulin A-type myeloma

Cited by 12 publications

References 25 publications

Sialyl Salivary–Type Amylase Associated with Ovarian Cancer

Sialyl Salivary–Type Amylase Associated with Ovarian Cancer

Hyperamylasaemia and multiple myeloma

In vitro excess ammonia production in human myeloma cell lines

Contact Info

Product

Resources

About